10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Phase 1/2 Completed 72 enrolled Spectrum Pharmaceuticals, Inc Memorial Sloan Kettering Cancer Center · collab National Cancer Institute (NCI) · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's lymphoma.

Timeline

Start: 2002-08
Primary completion: 2009-03
Completion: 2009-03

Publications

Results O'Connor OA, Horwitz S, Hamlin P, Portlock C, Moskowitz CH, Sarasohn D, Neylon E, Mastrella J, Hamelers R, Macgregor-Cortelli B, Patterson M, Seshan VE, Sirotnak F, Fleisher M, Mould DR, Saunders M, Zelenetz AD. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. J Clin Oncol. 2009 Sep 10;27(26):4357-64. doi: 10.1200/JCO.2008.20.8470. Epub 2009 Aug 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pralatrexate	Other / unclassified	30 mg/m2	Intravenous
Subject	Pralatrexate	Other / unclassified	45 mg/m2	Intravenous
Subject	Pralatrexate	Other / unclassified	135 mg/m2	Intravenous
Subject	Pralatrexate	Other / unclassified	270 mg/m2	Intravenous

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Summary

Timeline

Publications

Drugs

Indications